Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs